Assessing the Relationship between Gastrointestinal and Pancreatic Neuroendocrine Tumor Grade and Overall Survival: A Systematic Review and Meta-Analysis

Author:

Malik Preeti1,Patel Neel2ORCID,Khayyat Azadeh3,Asad Muhammad4,Dawoodi Sameer5,Chandramohan Sangeetha6,Unachukwu Nkechi7,Nasyrlaeva Bibimariyam8,Vaisyambath Laseena9,Chowdary Sriram B.10,Venkata Vikramaditya Samala11,Patel Urvish6ORCID

Affiliation:

1. Department of Pathology, Montefiore Medical Center, New York, NY 10467, USA

2. Department of Public Health, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA

3. Department of Internal Medicine, Brown University, Providence, RI 02903, USA

4. Department of Pathology and Laboratory Medicine, Weill Cornell Medical Center, New York Presbyterian Hospital, New York, NY 10065, USA

5. Department of Internal Medicine, Yale New Haven Health, Bridgeport Hospital, Bridgeport, CT 06610, USA

6. Department of Internal Medicine, MPH, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA

7. Department of Internal Medicine, Interfaith Medical Center, Brooklyn, NY 11213, USA

8. Department of Pathology, Siparadigm Diagnostic Informatics, Pine Brook, NJ 07058, USA

9. Department of Medicine, Markham Stouffville Hospital, Markham, ON L3P7P3, Canada

10. Department of Internal Medicine, Geisinger Community Medical Center, Scranton, PA 18510, USA

11. Department of Internal Medicine, Cheshire Medical Center, Dartmouth Hitchcock Medical Center, Keene, NH 03431, USA

Abstract

Background: Neuroendocrine tumors (NET) are a rare group of epithelial neoplasms present in the gastrointestinal tract (GI) (67.5%) and bronchopulmonary tree (25.3–30%), and in 15% of cases, their primary sites cannot be identified. Although endoscopic screening, improvements in pathological techniques, and early detection have shown improvements in NET survival rates, the prognosis of advanced, metastatic, and poorly differentiated NET is very poor. In this study, we aimed to evaluate the effect of gastrointestinal and pancreatic (GEPs) NETs’ grade on overall survival. Method: We searched observational studies describing the overall survival or prognostic factors of primary GEP NETs from May 2011–May 2021 following the PRISMA guidelines. Studies describing the effect of primary grade 3 GEP NETs on overall survival were included. A meta-analysis was performed, and a pooled hazard ratio and their 95% confidence interval (95% CI) were obtained. Forest plots were created using random effects models and a sensitivity analysis was performed to account for the heterogeneity. Results: Seven studies with 7692 confirmed patients were included. In our meta-analysis, grade 3 GEP NETs were associated with higher odds of poor survival (pooled HR: 2.73; 95% CI: 1.36–5.47; p = 0.005), with a 92% heterogeneity between studies (p < 0.0001). To account for this heterogeneity, a sensitivity analysis was performed by removing two outlying studies (Fathi et al. and Foubert et al.) on funnel plots. The results after the sensitivity analysis did not change and still showed a significant association of grade 3 with a poor survival (pooled HR: 4.53; 95% CI: 3.54–5.78; p < 0.00001), with no heterogeneity between studies (p = 0.72; I2 = 0%). Conclusions: Our meta-analysis found that grade 3 GEP NETs are associated with poor survival and additional future studies are needed to identify other risk factors associated with poor survival in GEP NETs to improve their mortality.

Publisher

MDPI AG

Subject

Gastroenterology,Oncology,Immunology and Microbiology (miscellaneous),Hepatology

Reference24 articles.

1. Gastric Neuroendocrine Tumors (G-Nets): Incidence, Prognosis and Recent Trend Toward Improved Survival;Yang;Cell Physiol. Biochem.,2018

2. (2023, August 01). Cancer.net: Neuroendocrine Tumors/Introduction [Internet]. Available online: https://www.cancer.net/cancer-types/neuroendocrine-tumors/introduction.

3. (2023, August 01). Neuroendocrine Tumors: Statistics [Internet]. It Is Estimated That, Has Been Increasing for Years. Available online: https://www.cancer.net/cancer-types/neuroendocrine-tumors/statistics#:~:text=Overall%2C.

4. Carcinoid tumors;Robertson;Am. Fam. Physician,2006

5. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States;Dasari;JAMA Oncol.,2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3